Kairui Nephrology Doctor Group Files for IPO Following $8M Series A Funding to Become China's Leading Kidney Disease Healthcare Provider

According to VCBeat (WeChat ID: vcbeat), in July 2017, CareRay Physician Group, China’s first nephrology-focused physician group, secured $8 million in Series A financing from Data Capital.

In July 2017, CareRay Physicians Group, China’s first nephrology physician group, secured an $8 million Series A financing from Data Capital.

Founded in 2015, CareRay is the first and largest nephrologist group in China, dedicated to providing nephrology medical services and hospital operational management. Over the past two years, CareRay has evolved from a purely asset-light “physician group” into a comprehensive nephrology healthcare group with dozens of partner hospitals and its own medical institutions, and it plans to become the first publicly listed “nephrologist medical group” in China.

Kairui has secured an $8 million investment from Data Capital, which will be primarily allocated to recruiting healthcare management talent and constructing nephrology hospitals. By leveraging the advantages of Kairui Physician Group’s top-tier expert resources, full-time medical team, and operational management team, the company aims to establish a leading national chain of nephrology dialysis hospitals.Data Capital stated that it would continue to provide financial support to Kairui, which had previously secured RMB 10 million in financing from Puhua Capital in 2016.

Data Capital, established in 2010, is a comprehensive equity investment fund management platform focusing on early-to-growth stage investments. It currently directly manages six funds and participates in the management of two others, earning recognition as one of the “Top 10 Domestic Venture Capital Firms in China for 2015.” Puhua Capital, founded in 2004, has invested in more than 200 companies and currently manages nearly RMB 10 billion in capital. Its notable portfolio companies include 360, Tongcheng Travel, Momo, Lvmama, Youyuan, and Yunda Express. Puhua Capital was ranked 15th among the “Top 50 Best Chinese Private Equity Investment Institutions in 2016.”

Continuous investment from renowned investment firms indicates that capital markets are highly optimistic about Kairui’s business model and growth prospects.

Currently, primary care hospitals in China generally face challenges in nephrology treatment, including physician shortages, low standards of medical care, and inadequate facilities and services. Leveraging the strengths of its own physician group, CareRay recruits expert teams through multiple channels and introduces full-time medical and nursing talent. Through collaborative partnerships with primary care hospitals, it rapidly enhances local nephrology care capabilities, enabling patients to access top-tier specialist services from across China without leaving their local areas. By establishing closely integrated medical consortiums between academic leaders at tertiary (Grade III Class A) hospitals and primary care institutions, both the economic and social benefits of primary care hospitals are significantly improved.

Kairui also boasts a robust management team, with core members possessing extensive operational management experience in the healthcare industry. Adhering to the philosophy of “innovation, adaptation, and disruption,” the company implements a series of efficient management and incentive measures, resulting in significant performance improvements across its hospital projects. By leveraging a dual-talent model of “medical professionals + management experts,” Kairui supports hospital development, transforming its facilities into leading local specialized hospitals for nephrology. This approach not only provides local patients with superior, more professional technical care and services but also focuses on enhancing the hospitals’ profitability.

Currently, Kairui’s partner hospitals and self-owned hospitals are distributed across Beijing, Hebei, Henan, Shanxi, Guangxi, Inner Mongolia, and other regions. The company is expanding rapidly by adding more than ten new partners each year, with the goal of becoming a large-scale nephrology medical group comprising over 100 medical institutions in the future.

“I have always felt that the business model founded by Lin Hai and his team is quite pragmatic. They not only understand the needs of Chinese kidney disease patients and China’s healthcare system, but also boast a professional team comprising both medical and operational management professionals, with clear strategic thinking and high execution efficiency,” Ye Weigang, Founder and Managing Partner of Data Capital, told VCBeat.

Ye Weigang holds the qualifications of U.S. Certified Public Accountant (CPA) and Certified Management Accountant (CMA), and earned an MBA from Harvard University. He has successfully led investments in well-known enterprises such as Daqo New Energy (NYSE: DQ) and Chuanyi Instrument Group (603100). With over 15 years of professional experience, he specializes in private equity investment, entrepreneurship, senior corporate management, and consulting.

Likewise, Puhua Capital has high expectations for Kairui. “Nephrology care, the sector in which Kairui operates, is a massive niche market within the healthcare industry, valued at hundreds of billions of yuan. Kairui itself boasts strong medical resources and a management team with profound insights into the industry. We are very confident in its future,” said Wang Jun, Partner at Puhua Capital.

In the future, CareRay will focus on the essence of medical service quality, firmly securing the two most critical endpoints of the industry chain—physicians and hospitals—and enhancing its operational management capabilities. As the performance of multiple hospitals rapidly improves, CareRay’s brand value will rise swiftly.

Kaierui will also deepen its collaboration with chronic kidney disease (CKD) management clinics and kidney disease insurance providers, while extending its reach into the industrial chain of medical devices, consumables, and pharmaceuticals, as well as internet healthcare. The company’s future valuation is expected to reach billions of yuan. To integrate high-quality resources, Kaierui plans to employ various capital operation strategies, including establishing merger and acquisition funds, to consolidate more promising small and medium-sized hospitals and innovative enterprises with outstanding technologies in the field of nephrology and dialysis, thereby establishing Kaierui as a leading brand in kidney disease medical services.

Lin Hai, founder of Kairui, stated, “We are committed to joining forces with more social capital to forge ahead, integrating resources across the vast field of nephrology, and creating a new industrial chain that combines management with healthcare.”